LPL and hereditary disease: Encouragingly, recent studies document several therapeutic successes of AAV-based gene therapy for genetic diseases in clinical trials [47,48,49,50,51,52,53,54,56,57,58], and Glybra, which involves the genetic delivery of lipoprotein lipase (LPL) by intramuscular injection of AAV1 vector to treat LPL deficiency disease, has just been licensed in Europe [55].